The strong beat on both revenue and EPS, combined with record demand carried into Q3, supports a bullish outlook for FENC. Monitor upcoming HC Wainwright conference (Sept 14-17) for further commercial updates and potential guidance on expanded AYA and adult market penetration.
Price Chart
Executive Summary
Fennec Pharmaceuticals reported Q2 2026 net product sales of $17.1M, up 78% YoY from $9.7M, and GAAP diluted EPS of $0.05, a 127.3% beat vs $0.02 consensus. Record non-GAAP adjusted EBITDA of $2.8M (vs -$1.2M a year ago) and a seventh consecutive quarter of growth confirm strong commercial execution for PEDMARK, which should drive continued upside as field sales expansion gains traction.
Key Financial Metrics
Key Facts
- Q2 2026 net product sales $17.1M, up 78% YoY from $9.7M
- GAAP diluted EPS $0.05 vs consensus $0.02 (beat +127.3%)
- Non-GAAP adjusted EBITDA of $2.8M vs -$1.2M in prior year period
- Record demand carried into Q3 2026; seventh consecutive quarter of growth
- Cash and equivalents $41.2M as of June 30, 2026, sufficient to fund current operating plan
- Selling & marketing expenses doubled to $10.7M from $4.8M YoY from expanded sales force
Financial Impact
Revenue growth of $17.1M in the quarter, contributing to positive GAAP net income of $1.97M vs a loss of $3.15M a year ago
Risk Factors
- Selling & marketing expenses doubled YoY; profitability depends on sustaining revenue growth to cover rising SG&A
- Dependence on single product PEDMARK for revenue; competitive or regulatory changes could impact adoption
- Contract liability of $24.1M (current + long-term) from Norgine licensing may distort cash flow comparisons
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342578 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.15 (−1.17%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.15 (−15.63%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.15 (−15.63%) |
Aug 11, 2026 11w ago | Press Release | $12.78 | awaiting T+60 | — | $10.15 (−20.58%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.15 (+10.45%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.15 (+2.63%) |
May 18, 2026 23w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.15 (+4.00%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.15 (+9.85%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.15 (+47.10%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.15 (+62.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers